Explore this article's sources with AI
Follow PeptideMethods on Google
Can Wegovy Affect an Alcohol Interlock?
A single Wegovy case report proposes a ketone-to-isopropanol route for disputed alcohol interlock results, but lacks chemical confirmation.
Why we wrote this. A legally sensitive case report needs a clear separation between a plausible chemical mechanism and evidence that confirms it in one person.
In this article (5 sections)
A 2026 case report describes a 45-year-old woman who recorded two positive ignition interlock tests within days of increasing Wegovy from 1.0 mg to 1.7 mg. She denied drinking alcohol and reported several years of sobriety[1]. The author proposed that reduced food intake after the dose increase could have raised ketone production, with some acetone converted to isopropanol that the device detected. This is a plausible explanation, not proof that semaglutide caused either result.
The report was published online in The Medico-Legal Journal on November 12, 2026. It concerns one person and a disputed measurement, not a controlled study of breath tests in people using GLP-1 receptor agonists. The public abstract does not report laboratory confirmation of acetone or isopropanol, a measured ketone level, or an independent analysis of the interlock device[1]. Those missing checks sharply limit what the case can establish.
What the case report says happened
The woman was prescribed Wegovy, the semaglutide brand used for chronic weight management. According to the report, the two positive interlock readings occurred within days of a dose increase from 1.0 mg to 1.7 mg. The Wegovy label includes those strengths in its escalation schedule[2]. A standard dose step, however, does not explain a breath result by itself.
The case history included her denial of alcohol use, testimony about several years of sobriety, continued employment, and otherwise compliant use of the interlock[1]. These details explain why the result was disputed. They do not independently determine what chemical reached the sensor. The abstract does not give the numerical readings, the exact interval between dosing and testing, her food intake, blood glucose, medications, or whether another breath or blood test was taken at the same time.
A case report is useful when it identifies a possible event that deserves closer testing. It cannot estimate how often that event occurs. There is no comparison group here, no planned exposure protocol, and no repeated chemical testing that links dose escalation to a specific interferent. The timing supports a hypothesis. It does not establish causation.
How the proposed chemistry could work
Ignition interlock devices commonly use an electrochemical fuel-cell sensor. The sensor is intended to respond to ethanol, but it can also respond to other alcohols, including isopropanol[1]. Acetone itself is not an alcohol. Under some metabolic conditions, the body can reduce acetone to isopropanol through an alcohol dehydrogenase pathway.
The case author's proposed sequence begins with lower caloric intake after the Wegovy increase. Greater reliance on fat metabolism could increase ketone bodies, including acetone. Conversion of some acetone to isopropanol could then create a fuel-cell response even without ethanol consumption[1]. Each step is biologically possible, but the report did not directly measure the chain in this patient.
A 2006 forensic case described the same chemical pathway. It involved a 59-year-old man on a very-low-calorie ketogenic diet whose alcohol interlock prevented his car from starting. The authors attributed the result to ketosis, conversion of acetone to isopropanol, and the sensor's response to isopropanol[3]. That case involved a ketogenic diet, not semaglutide.
A 1995 forensic case identified acetone and isopropanol, but no ethanol, in a motorist's blood after a positive electrochemical breath screen. An infrared evidential instrument detected an interferent[4]. That person had severe metabolic ketoacidosis and a different clinical history. It supports the chemical pathway while also showing what the 2026 report lacks: direct measurement of the suspected compounds.
What the report does not prove
The report does not show that Wegovy routinely causes false-positive alcohol tests or that a dose increase produces enough isopropanol to trigger an interlock. Device error, environmental exposure, mouth alcohol, another metabolic condition, or an unreported source of ethanol also remain possible. The available abstract offers a proposed explanation after two events in one person.
The report also cannot settle a legal or employment dispute. Device logs, calibration records, contemporaneous confirmatory tests, medical records, and the rules of the relevant jurisdiction may all affect how a result is evaluated. A journal case can alert clinicians and forensic specialists to a possible interferent, but it is not a substitute for evidence from the event under review.
No frequency estimate is possible. The paper does not tell us how many people using semaglutide have taken interlock tests without a disputed result. Without that denominator, two readings in one case cannot be converted into a risk percentage. Broader information about the medicine and its known adverse effects belongs in the semaglutide safety overview, not inferences from this report alone.
What stronger evidence would require
A stronger investigation would record the device model, calibration status, numerical readings, timing, diet, glucose, blood ketones, breath acetone, and blood or breath isopropanol. A second method that can distinguish ethanol from other volatile compounds would help test whether the fuel-cell signal came from an interferent. Repeated measurements before and after dose escalation could examine timing, although they would still need appropriate clinical oversight.
Research across a larger group would also need a comparison condition and a denominator. It could ask how often confirmed non-ethanol fuel-cell responses occur among people using GLP-1 medicines, whether reduced caloric intake or ketosis predicts them, and whether results differ by device. Until those data exist, the report is best read as a signal for forensic follow-up rather than a known adverse effect.
How to read this case
The careful conclusion is narrow. A disputed pair of interlock results appeared soon after one Wegovy dose increase, and established chemistry offers a possible route from increased ketone production to a fuel-cell response. The report did not confirm that route in the patient. Readers should keep the proposed mechanism and the missing measurements in view at the same time.
Anyone using prescribed semaglutide should not change or stop treatment based on a single case report. Questions about symptoms, reduced food intake, or metabolic illness require clinical assessment. Questions about a disputed interlock result require prompt preservation of the device record and advice from qualified medical, forensic, and legal professionals familiar with the specific case.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
Can Wegovy cause a false-positive alcohol interlock test?
One 2026 case report proposes that possibility, but it did not chemically confirm the cause. It cannot show how often the event occurs or establish that Wegovy caused the readings.
Why might an interlock detect isopropanol?
Fuel-cell sensors can respond to alcohols other than ethanol. Under some metabolic conditions, acetone from ketone production can be converted to isopropanol, which may produce a sensor response.
Did the case report measure ketones or isopropanol?
The public abstract does not report measured ketones, acetone, or isopropanol, nor an independent device analysis. The proposed pathway therefore remains unconfirmed in this patient.
Should someone stop Wegovy after a disputed test?
A single case report is not a reason to change prescribed treatment. Treatment questions belong with a qualified clinician, while disputed device results require case-specific forensic and legal review.
Sources
- [1]Olson A. GLP-1 dose escalation and disputed ignition interlock alcohol results: Case report. Med Leg J. 2026. PMID 43018099.Tier 1 · primary↩
- [2]Wegovy (semaglutide) prescribing information. DailyMed.Tier 1 · primary↩
- [3]Jones AW, Rossner S. False-positive breath-alcohol test after a ketogenic diet. Int J Obes. 2007. PMID 16894360.Tier 1 · primary↩
- [4]Jones AW, Andersson L. Biotransformation of acetone to isopropanol observed in a motorist involved in a sobriety check. J Forensic Sci. 1995. PMID 7595310.Tier 1 · primary↩
No revisions yet. First published .